The Movie, Artificial-A Biographical Comedy-Drama. 2026

Artificial is a 2026 biographical comedy-drama directed by Luca Guadagnino and written by Simon Rich. (see trailer at bottom of page)💚

What the Movie Is About

The Rise of OpenAI: The film spans two decades of machine learning research, tracing the journey from early academic labs in 2003—where computer scientist Ilya Sutskever studies under AI pioneer Geoffrey Hinton—to the creation and explosive commercialization of ChatGPT.
The Core Conflict: It centers on the ideological clash between the idealistic co-founder Ilya Sutskever (played by Yura Borisov) and the commercially driven CEO Sam Altman (played by Andrew Garfield) as generative AI shifts from abstract theory to high-stakes corporate power.
The 2023 Boardroom Crisis: The narrative builds up to the dramatic November 2023 internal crisis at OpenAI, focusing on the high-tension friction over safety, ethics, and corporate control.
Key Figures: Alongside Altman and Sutskever, the movie features dramatized portrayals of figures like Mira Murati (Monica Barbaro) and Elon Musk (Ike Barinholtz).

The film is distributed by Neon. 

The plot of is heavily grounded in the rapid transformation of OpenAI from a small academic non-profit into a corporate juggernaut, culminating in one of the most chaotic weeks in Silicon Valley history.

The primary real-life events that inspired the film include:

1. The Ideological Rift: Safety vs. Commercialization

At the heart of the film is a real philosophical divide that split the company's founders:

• The Non-Profit Mission: OpenAI was founded in 2015 as a non-profit research lab dedicated to creating safe Artificial General Intelligence (AGI) that benefits all of humanity.
• The Commercial Pivot: To fund the massive computing power required for deep learning, Sam Altman restructured the company to introduce a "capped-profit" commercial subsidiary. This shift created deep friction with original board members and Chief Scientist Ilya Sutskever, who feared that commercial pressures were overshadowing crucial AI safety protocols. 

2. The November 2023 Boardroom Coup

The narrative peak of the film mirrors the multi-day corporate thriller that began on Friday, November 17, 2023: 

• The Surprise Firing: The non-profit board, spearheaded by Sutskever and board members like Helen Toner, abruptly fired CEO Sam Altman via a surprise Google Meet call. The board publicly stated that Altman was "not consistently candid in his communications," hindering their ability to govern.
• The Executive Fallout: Co-founder and President Greg Brockman resigned immediately in protest. CTO Mira Murati was briefly installed as interim CEO before the board bypassed her to appoint former Twitch CEO Emmett Shear. 

3. The 95% Employee Mutiny

The resolution of the crisis came down to an unprecedented level of employee solidarity:

• The Microsoft Play: Over the weekend, Microsoft CEO Satya Nadella announced he was hiring Altman and Brockman to lead a brand-new internal AI division, stripping the OpenAI board of its leverage.
• The Ultimatum: In response, roughly 745 out of OpenAI’s 770 employees signed a joint letter demanding the board resign and reinstate Altman, threatening to quit and move to Microsoft if their demands weren’t met. 

4. The U-Turn and Reinstatement

Faced with the total destruction of the company, Ilya Sutskever publicly expressed regret on social media for his role in the ouster. By Wednesday, November 22, Altman made a triumphant return to the headquarters as CEO. The original board members who pushed him out were dismantled and replaced by a new corporate-friendly interim board. 

Subsequent Real-Life Fallout

The film's exploration of "technological isolation" captures the real-world aftermath of this coup. In May 2024, Ilya Sutskever officially left OpenAI to form a competing venture, Safe Superintelligence Inc. (SSI), explicitly focusing on building AI aligned entirely with safety rather than immediate commercial scale. The Trailer: 

💚https://youtu.be/rDZplZFnbOk?si=f97plnQmFZMkmO7E

Meanwhile, Can Aging Be Reversed?

Research linked to Harvard scientist David Sinclair has shown promising results in animals using a process called partial epigenetic reprogramming. Now, Life Biosciences, a company Sinclair co-founded, has received FDA clearance to begin human testing of its experimental gene therapy, ER-100.

The treatment activates three genes known as OCT4, SOX2, and KLF4. These genes are designed to help reset certain age-related changes in cells while preserving their original identity. Earlier animal research reported dramatic improvements in biological aging markers, but whether similar results can occur safely in humans remains unknown.

The first human trial will focus on serious eye conditions, including glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). Both conditions can damage retinal ganglion cells, which carry visual information from the eyes to the brain.

Currently, no established treatment can reliably regenerate these lost nerve cells. ER-100 aims to investigate whether cellular reprogramming could help restore their function.

Finally, My Photo of the Day: